Ledyard National Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ledyard National Bank’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-80	Closed	-$7K	–	752
2017 Q4	$7K	Hold	80	–	–	﹤0.01%	691
2017 Q3	$7K	Buy	+80	New	+$7.07K	﹤0.01%	685
2016 Q2	–	Sell	-19	Closed	-$2K	–	595
2016 Q1	$2K	Hold	19	–	–	﹤0.01%	664
2015 Q4	$2K	Hold	19	–	–	﹤0.01%	664
2015 Q3	$2K	Hold	19	–	–	﹤0.01%	641
2015 Q2	$3K	Buy	+19	New	+$2.35K	﹤0.01%	646

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ledyard National Bank's BMRN Position: Q1 2018 in Review

Ledyard National Bank sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2018, closing a stake of 80 shares — an estimated $7K sold.

Ledyard National Bank first reported a position in BMRN in Q2 2015 and held it in 6 quarters. The position peaked at $7K in Q4 2017. 429 funds tracked by Wall St. Rank hold BMRN as of Q1 2018.

Ledyard National Bank reported no remaining BioMarin Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Ledyard National Bank sold 80 BioMarin Pharmaceuticals shares in Q1 2018, an estimated $7K.
Ledyard National Bank first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 6 quarters.
Ledyard National Bank's BioMarin Pharmaceuticals position peaked at $7K in Q4 2017.
429 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2018.

Based on Ledyard National Bank's 13F filing for Q1 2018, filed 16 Apr 2018.